BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18299943)

  • 1. ZM336372, a Raf-1 activator, causes suppression of proliferation in a human hepatocellular carcinoma cell line.
    Deming D; Geiger P; Chen H; Vaccaro A; Kunnimalaiyaan M; Holen K
    J Gastrointest Surg; 2008 May; 12(5):852-7. PubMed ID: 18299943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways.
    Kunnimalaiyaan M; Ndiaye M; Chen H
    Surgery; 2007 Dec; 142(6):959-64; discussion 959-64. PubMed ID: 18063082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells.
    Van Gompel JJ; Kunnimalaiyaan M; Holen K; Chen H
    Mol Cancer Ther; 2005 Jun; 4(6):910-7. PubMed ID: 15956248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells.
    Kappes A; Vaccaro A; Kunnimalaiyaan M; Chen H
    J Surg Res; 2006 Jun; 133(1):42-5. PubMed ID: 16603190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
    Yang R; Piperdi S; Gorlick R
    Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801.
    Yamaguchi F; Hirata Y; Akram H; Kamitori K; Dong Y; Sui L; Tokuda M
    BMC Cancer; 2013 Oct; 13():468. PubMed ID: 24112473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W; Xu B; Li Q; Jiang D; Yan S
    Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single high dose irradiation induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cells through the Ras/Raf/MEK/ERK pathways.
    Tian X; Geng J; Zheng Q; Wang L; Huang P; Tong J; Zheng S
    Int J Radiat Biol; 2020 Jun; 96(6):740-747. PubMed ID: 32039644
    [No Abstract]   [Full Text] [Related]  

  • 12. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.
    Ghousein A; Mosca N; Cartier F; Charpentier J; Dupuy JW; Raymond AA; Bioulac-Sage P; Grosset CF
    Liver Int; 2020 Jan; 40(1):240-251. PubMed ID: 31612616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
    Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
    Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
    Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of p21CIP1 expression mediated by ERK-dependent and -independent pathways contributes to hepatocyte growth factor-induced inhibition of HepG2 hepatoma cell proliferation.
    Shirako E; Hirayama N; Tsukada Y; Tanaka T; Kitamura N
    J Cell Biochem; 2008 May; 104(1):176-88. PubMed ID: 18004740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
    Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
    Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
    Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk.
    Zhang J; Lan SJ; Liu QR; Liu JM; Chen XQ
    Mol Pharmacol; 2013 May; 83(5):1109-19. PubMed ID: 23478801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib paradoxically activates the RAS/RAF/ERK pathway in polyclonal human NK cells during expansion and thereby enhances effector functions in a dose- and time-dependent manner.
    Lohmeyer J; Nerreter T; Dotterweich J; Einsele H; Seggewiss-Bernhardt R
    Clin Exp Immunol; 2018 Jul; 193(1):64-72. PubMed ID: 29573266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
    Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
    Mol Cancer Ther; 2007 Mar; 6(3):1151-8. PubMed ID: 17363508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.